EVOTEC SE ADR 1/2 O.N. Total Liabilities
EVOTEC SE ADR 1/2 O.N. total liabilities. Based on the latest financial reports, EVOTEC SE ADR 1/2 O.N. (EVTA) has total liabilities worth €900.24 Million EUR (≈ $1.05 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check EVOTEC SE ADR 1/2 O.N. liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of EVOTEC SE ADR 1/2 O.N. (2021–2025)
Total liabilities of EVOTEC SE ADR 1/2 O.N. from 2021 to 2025. This chart illustrates how EVOTEC SE ADR 1/2 O.N.'s total liabilities have evolved over time, based on quarterly financial data. Explore EVTA long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
EVOTEC SE ADR 1/2 O.N. Competitors by Total Liabilities
The table below lists competitors of EVOTEC SE ADR 1/2 O.N. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Precision Wires India Limited
NSE:PRECWIRE
|
India | Rs-7.72 Billion |
|
Shen Ma Industry Co Ltd
SHG:600810
|
China | CN¥18.63 Billion |
|
NatureCell Co.Ltd
KQ:007390
|
Korea | ₩8.60 Billion |
|
Jiangsu General Science Tech
SHG:601500
|
China | CN¥8.47 Billion |
|
Arbutus Biopharma Corp
NASDAQ:ABUS
|
USA | $15.29 Million |
|
Kornit Digital Ltd
NASDAQ:KRNT
|
USA | $64.70 Million |
|
JC Finance & Tax Interconnect Holdings Ltd
SHE:002530
|
China | CN¥822.56 Million |
|
Six Flags Entertainment Corporation
NYSE:FUN
|
USA | $7.32 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down EVOTEC SE ADR 1/2 O.N.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see EVTA current and non-current assets.
Liquidity & Leverage Metrics
EVOTEC SE ADR 1/2 O.N. Total Liabilities Ratios Explained
EVOTEC SE ADR 1/2 O.N. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how EVOTEC SE ADR 1/2 O.N.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for EVOTEC SE ADR 1/2 O.N. (2021–2025)
The table below shows the annual total liabilities of EVOTEC SE ADR 1/2 O.N. from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €900.24 Million ≈ $1.05 Billion |
-6.22% |
| 2024-12-31 | €959.98 Million ≈ $1.12 Billion |
-15.24% |
| 2023-12-31 | €1.13 Billion ≈ $1.32 Billion |
+5.84% |
| 2022-12-31 | €1.07 Billion ≈ $1.25 Billion |
+24.79% |
| 2021-12-31 | €857.48 Million ≈ $1.00 Billion |
-- |
About EVOTEC SE ADR 1/2 O.N.
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammati… Read more